314.98—Postmarketing reports.
        
        (a) 
         Except as provided in paragraph (b) of this section, each applicant having an approved abbreviated new drug application under  § 314.94 that is effective shall comply with the requirements of  § 314.80 regarding the reporting and recordkeeping of adverse drug experiences.
    
    
        
        (b) 
         Each applicant shall submit one copy of each report required under  § 314.80 to the Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.
    
    
        
        (c) 
         Each applicant shall make the reports required under  § 314.81 and  section 505(k) of the act for each of its approved abbreviated applications.